Background Asthma is a major cause of morbidity in children, despite the availability of
various treatments. In adults, tiotropium—a long-acting muscarinic antagonist—as add-on …

Background Results from phase III clinical trials in adults and phase II clinical trials in
children and adolescents demonstrate that tiotropium is an effective treatment when added …

Tiotropium bromide is a long-acting muscarinic antagonist (LAMA) and is the only LAMA
licensed for management for patients'≥ 6 years old with severe asthma who have …

Background The role of tiotropium for the treatment of adolescents with asthma has not yet
been clearly defined. Objective To assess the efficacy and safety of inhaled tiotropium in …

Background Studies in adults and adolescents have demonstrated that tiotropium is
efficacious as an add-on therapy to inhaled corticosteroids (ICSs) with or without other …

Background Recently published data support the benefits and safety of the once‐daily (OD)
long‐acting anticholinergic tiotropium bromide bronchodilator for the treatment of …

Introduction Tiotropium, a once-daily long-acting anticholinergic agent, has been shown to
be an efficacious and safe add-on treatment for adults with symptomatic asthma, despite …

Asthma is one of the most common chronic diseases in children, with a high proportion of
patients demonstrating poor control despite the availability of disease management …

Abstract Background The Global Initiative for Asthma has only recently added tiotropium
bromide as adjunct controller therapy in severe asthma (Step 4 or 5) in adults (2015) and …

Background Few studies have assessed the safety and efficacy of potential asthma
medications in children younger than 5 years. We descriptively assessed the safety and …